Countries Austria Iran Brazil Israel Bulgaria Italy Canada - - PowerPoint PPT Presentation

Countries

Austria Iran Brazil Israel Bulgaria Italy Canada Japan Chile Kenya China Mexico Colombia New Zealand Germany Netherlands Dominican Republic Pakistan Finland Peru Great Britain Philippines Guatemala Singapore Hungary Switzerland India United States (2)

Topics ranked in terms of importance when other non-rank responses are factored in

*Other: Shared decision making/patient participation, Best practices to follow

7 22

5 10 15 20 25 Yes No

Yes:

Italy, Austria, Switzerland, Germany, China, Great Britain, Netherlands

No:

United States (2), Hungary, Kenya, India, Guatemala, Chile, Israel, Finland, Mexico, Canada, Brazil, Dominican Republic, Colombia, Peru, New Zealand, Philippines, Iran, Singapore, Bulgaria, Japan, Pakistan

19 16 12 6 2 4 6 8 10 12 14 16 18 20 THEIR PRIMARY DOCTOR WILL TRIAGE THEM TO A CANCER CENTER THEY CONTACT YOUR ORGANIZATION BY PHONE OR EMAIL FOR A RECOMMENDATION PERUSE A LIST PROVIDED IN YOUR OR ANOTHER ORGANIZATIONS' WEBSITE OTHER

19 8 5 12 13 4 DISTANCE FINANCIAL/HEALTH INSURANCE PERSONAL AND CULTURAL BELIEFS FEAR OF OFFENDING CURRENT PHYSICIAN LACK OF GIST SPECIALISTS *OTHER

*Other: Family physicians, Patients do not know availability, Health insurance, Ignorance of importance of treatment in specialized center

20 4 3 13 6 7 1 10 3 7 7 5 10 15 20 25 Easily accessible Somewhat accessible Not easily accessible Not at all accessible Imatinib as 1st line treatment Sunitinib as 2nd line treatment Regorafenib as 3rd line treatment

Not easily accessible

Imatinib:

Peru, Philippines, Pakistan

Sunitinib:

Chile, Dominican Republic, Peru, Philippines, Iran, Singapore, Pakistan

Regorafenib:

Kenya, Germany, China, Dominican Republic, Singapore, Pakistan

Not at all accessible

Sunitinib:

Guatemala

Regorafenib:

India, Guatemala, Mexico, Colombia, Philippines, Iran, Great Britain

12 9 1 5 15 7 1 4 14 5 3 5 9 6 4 8 TOTALLY REIMBURSABLE SOMEWHAT REIMBURSABLE NOT EASILY REIMBURSABLE NOT AT ALL REIMBURSABLE Imatinib - Adjuvant Imatinib-metastatic/recurrent disease Sunitinib Regorafenib

Not easily reimbursable

Imatinib – Adjuvant:

Hungary

Imatinib – Metastatic:

Peru

Sunitinib:

Chile, Dominican Republic, Peru

Regorafenib:

Germany, China, Chile, Dominican Republic

Not at all reimbursable

Imatinib – Adjuvant:

Kenya, India, Iran, Singapore, Pakistan

Imatinib – Metastatic:

India, Iran, Singapore, Pakistan

Sunitinib:

India, Philippines, Iran, Singapore, Pakistan

Regorafenib:

India, Mexico, Colombia, Philippines, Iran, Singapore, Bulgaria, Pakistan

4 2 15 6 2 4 6 8 10 12 14 16 HAVE VERY EASY ACCESS HAVE SOMEWHAT EASY ACCESS DO NOT HAVE EASY ACCESS DO NOT HAVE ACCESS AT ALL

Have Very Easy Access:

United States, Israel, Brazil, Netherlands

Have Somewhat Access:

Switzerland, Germany

Do Not Have Easy Access:

Italy, Hungary, India, United States, Switzerland, Chile, Finland, Mexico, Canada, Dominican Republic, Peru, Great Britain, Singapore

Do Not Have Access at All:

Kenya, Great Britain, Colombia, Philippines, Iran, Bulgaria

23 20 22 16 4 5 10 15 20 25 PHYSICIANS PATIENT ADVOCACY GROUPS INTERNET OTHER PATIENTS PHARMACY INSURANCE COMPANY GOVERNMENT FAMILY/CAREGIVER

10 13 4 2 4 6 8 10 12 14 VERY SIGNIFICANT SOMEWHAT SIGNIFICANT NOT VERY SIGNIFICANT NOT AT ALL SIGNIFICANT

Very Significant:

Italy, Hungary, Guatemala, Chile, Israel, Finland, Brazil, Dominican Republic, Colombia

Somewhat Significant:

US, Kenya, India, Switzerland, Germany, China, Mexico, Canada, Peru, Philippines, Pakistan

Not Very Significant:

US, Great Britain, Japan

Not At All Significant:

N/A

make dissemination of information to patients a priority the next step is to target these countries for improvement become a priority of the patient advocacy community share successful strategies and pair these groups with others that can use help

Image credit: http://www.sekari.com/google-tests-split-view-screen-for-different-languages/